Trump's MFN pricing deals with nine more drugmakers brings total to 26

1 September 2026

The White House has announced that nine additional pharmaceutical manufacturers have signed most-favored-nation (MFN) pricing agreements with the Trump administration, bringing the total number of companies with such deals to 26, covering an estimated 89% of the US branded drug market.

These nine companies are Swiss ophthalmic device maker Alcon (NYSE/SIX: ALC), Japanese pharma major Astellas Pharma (TSE: 4503), Chinese-American biotech BeOne Medicines (Nasdaq: ONC), US rare disease specialist BridgeBio Pharma (Nasdaq: BBIO), Australian biotherapeutics group CSL Limited (ASX: CSL), Japanese pharma major Kyowa Kirin (TYO: 4151), Indian generics major Sun Pharmaceutical Industries (BSE/NSE: SUNPHARMA), Israeli pharma major Teva Pharmaceutical Industries (NYSE: TEVA), and Belgian biopharmaceutical company UCB (Euronext Brussels: UCB).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK